Royalty Pharma plc

NasdaqGS RPRX

Royalty Pharma plc Market Capitalization on January 14, 2025: USD 17.69 B

Royalty Pharma plc Market Capitalization is USD 17.69 B on January 14, 2025, a 5.95% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.
  • Royalty Pharma plc 52-week high Market Capitalization is USD 18.42 B on February 26, 2024, which is 4.08% above the current Market Capitalization.
  • Royalty Pharma plc 52-week low Market Capitalization is USD 14.31 B on December 19, 2024, which is -19.15% below the current Market Capitalization.
  • Royalty Pharma plc average Market Capitalization for the last 52 weeks is USD 16.41 B.
Key data
Date Market Capitalization Share Price Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S)
Market news
Loading...
NasdaqGS: RPRX

Royalty Pharma plc

CEO Mr. Pablo Gerardo Legorreta
IPO Date June 16, 2020
Location United States
Headquarters 110 East 59th Street
Employees 75
Sector Health Care
Industries
Description

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Similar companies

IKNA

Ikena Oncology, Inc.

USD 1.51

-1.95%

PRME

Prime Medicine, Inc.

USD 2.70

-2.53%

ADPT

Adaptive Biotechnologies Corporation

USD 6.07

-6.04%

MDGL

Madrigal Pharmaceuticals, Inc.

USD 274.12

-9.74%

AKRO

Akero Therapeutics, Inc.

USD 21.87

-3.36%

DAWN

Day One Biopharmaceuticals, Inc.

USD 11.16

-3.46%

IOVA

Iovance Biotherapeutics, Inc.

USD 5.89

1.90%

APLS

Apellis Pharmaceuticals, Inc.

USD 27.69

-3.15%

DNA

Ginkgo Bioworks Holdings, Inc.

USD 8.56

-3.39%

ASND

Ascendis Pharma A/S

USD 131.57

-1.84%

BPMC

Blueprint Medicines Corporation

USD 102.56

-0.77%

AMLX

Amylyx Pharmaceuticals, Inc.

USD 3.13

-1.57%

StockViz Staff

January 15, 2025

Any question? Send us an email